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ABSTRACT 
 
The biodistribution of extracellular vesicles (EVs) is a fundamental question in the field of circulating 
biomarkers, which has recently gained attention. Despite the capabilities of nuclear imaging methods such 
as single photon emission computed tomography (SPECT), radioisotope labeling of EVs and the use of 
the aforementioned methods for in vivo studies hardly can be found in the literature. In this paper we 
describe a novel method for the radioisotope labeling of erythrocyte-derived EVs using the 99mTc-
tricarbonyl complex. Moreover, the capability of the developed labeling method for in vivo biodistribution 
studies is demonstrated in a mouse model. We found that the intravenously administered, 99mTc-labelled 
EVs mostly accumulated in the liver, and in the spleen. The in vivo stability of the labeled EVs was 
assessed by the comparison of the obtained biodistribution of EVs with that of the free 99mTc-tricarbonyl. 
According to our data, only a minor fraction of the radioactive label became detached from the EVs.  
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Introduction 
Extracellular vesicles (EVs) are recently recognized as key players in many physiological and pathological 
conditions.1–6 EVs are not only present in all human body fluids, but also can be found for example in 
ocean water7 and beer8, due to the fact that yeasts and other microorganisms also release EVs. The clinical 
relevance of EVs was first recognized for their diagnostic use as biomarkers of different diseases5. 
Recently the therapeutic application of EVs is also emerging9,10, for example, the application of dendritic 
cell (DC) derived exosomes for cancer treatment was recently under investigation in a clinical trial 
(NCT01159288). Understanding the role of these membrane vesicles in intercellular communication and 
also their applicability as vehicles for drug delivery requires the investigation of their biodistribution. The 
in vivo fate of EVs has only been addressed in the last few years, and most studies used fluorescent 
imaging for this purpose.11–18 In these studies EVs were either labeled with a membrane dye13,18 or 
engineered to display a membrane reporter (e.g. Gaussia luciferase), and administered exogenously15 or 
utilized endogenously produced, genetically modified EVs (such as GFP-tagged CD63 bearing EVs)19. On 
the other hand, the application of nuclear imaging techniques such  as single photon emission computed 
tomography (SPECT) or positron emission tomography (PET) utilizing isotopically labeled EVs hardly 
can be found in the literature, despite the fact that these techniques have indisputable advantages over 
fluorescent imaging regarding quantitative measurement of the biodistribution of the labeled compounds.20  
In this paper we report a novel method for radioisotope labeling of EVs using 99mTc-tricarbonyl complex, 
and demonstrate the applicability of this method for the non-invasive assessment of the biodistribution of 
erythrocyte-derived EVs using SPECT/CT. 
 
Material and Methods 
Preparation of erythrocyte vesicles 
Erythrocyte vesicles were isolated from freshly outdated erythrocyte concentrates (Hungarian National 
Transfusion Service). The erythrocyte concentrate was two-fold diluted in phosphate buffered saline 
(PBS, Sigma-Aldrich, P4417), and the red blood cells were removed by two centrifugation steps at 1500 x 
g for 20 minutes at 4 C. EVs in the erythrocyte-free supernatant were concentrated by ultracentrifugation 
(Thermo Sorvall WX Ultracentrifuge, T-1270 fixed angle rotor) at 130 000 x g for 30 min and washed 
once with PBS using the same parameters. After re-suspending the EV pellet in PBS, the sample was 
filtered through a 600 nm polycarbonate filter (Whatman® NucleporeTM), and finally snap frozen in 100 μl 
aliquots using liquid nitrogen and stored at -20 °C until use.  
Freeze-Fracture Transmission Electron Microscopy (FF-TEM) 
The vesicle sample (1-2 µl) was pipetted onto a gold sample holder, was frozen by plunging it 
immediately into partially solidified freon for 20 seconds and was stored in liquid nitrogen. Fracturing was 
performed at -100 °C in a Balzers freeze-fracture device (Balzers BAF 400D, Balzers AG, Vaduz, 
Liechtenstein). Replicas of the fractured faces etched at -100 °C were made by platinum-carbon 
shadowing and then cleaned with a water solution of surfactant and washed with distilled water. The 
replicas were placed on 200 mesh copper grids and examined in a MORGAGNI 268D (FEI, The 
Netherlands) transmission electron microscope. 
Size Exclusion Chromatography combined with Dynamic Light Scattering (SEC-DLS) 
SEC-DLS analysis was performed with a Jasco HPLC system (Jasco, Tokyo, Japan) consisting of a PU-
2089 pump, an UV-2075 UV/Vis detector and a W130i online DLS detector (Avid Nano, High Wycombe, 
UK) controlled by the Chromnav software v. 1.17.02. Sepharose CL-2B gel was used as a stationary phase 
filled in a Tricorn 5/200 glass column (GE Healthcare Life Sciences). CL-2B is a cross-linked agarose gel 
with fractionation range of 70-40,000 kDa for dextran, and was found to be suitable for purification of EV 
samples 21. The eluent was PBS, and the elution speed was 0.25 mL/min. The scattering intensity at 90 
degrees and the autocorrelation function accumulated for 3 seconds was measured with the DLS setup 
equipped with a 660 nm laser. The online DLS data were processed with the iSize 3.0 software (Avid 
Nano Ltd., High Wycombe, UK). 
 
Purification and concentration of erythrocyte derived EVs 
Prior to labeling of the erythrocyte-derived EVs obtained by differential centrifugation,  the EV sample 
was purified using a 10 mL plastic gravity column filled with the same Sepharose CL-2B gel used for the 
SEC-DLS investigation. 0.5 mL EV sample was introduced onto the column and PBS was used as the 
eluent. The EV-containing fraction corresponding to the void volume of the column was collected (1 mL) 
and further concentrated to 0.6 mL by using Vivaspin 500 centrifugal filters with 100 kDa MWCO 
(Sartorius Stedim Biotech GmbH). 
99mTc labeling of the purified erythrocyte derived EVs 
Radiolabeling of the erythrocyte-derived EVs was performed with the 99mTc-tricarbonyl complex 
[99mTc(CO)3(H2O)3]+ using a commercial kit (Isolink®, Mallinckrodt Medical B.V.), according to the 
manufacturer’s instructions. 1.2 GBq  [99mTcO4]- was eluted in 1 mL saline and added to the kit, followed 
by placing the vial into boiling water for 20 minutes. The basic solution was neutralized by the addition of 
approx. 200 µL 1 M HCl solution. 0.6 mL of the EV sample was added to 0.8 mL 99mTc-tricarbonyl 
complex solution (430 MBq) and incubated for 30 min at room temperature. Separation of the free 99mTc-
tricarbonyl was performed using a desalting column (ZebaTM Spin Desalting Column, 0.5 mL) applying the 
manufacturer’s instructions. 
 
In vivo SPECT/CT imaging 
In vivo imaging was carried out on male BALB/c mice (n=3, Charles River Hungary). The body mass of 
the experimental animals was 28 ± 5 g and they were 10-12 week old. Animal experiments were carried 
out at the Nanobiotechnology & In Vivo Imaging Center, Semmelweis University, with permission from 
the local institutional animal ethics committee no. XIV-I-001/29-7/2012 and in compliance with the 
relevant European Union and Hungarian regulations. Images were acquired with a NanoSPECT/CT Silver 
Upgrade (Mediso Ltd., Budapest, Hungary) sequential animal SPECT/CT imaging system. In the 
SPECT/CT experiment 15 ± 2 MBq of 99mTc-labelled erythrocyte EVs in 200 µl volume was injected into 
the tail vein of the mice. Control measurements (n=3) were performed by injecting 99mTc-tricarbonyl 
complex only. During the scans the animals were continuously anaesthetized using a mixture of 1-1.5% 
isoflurane and medical oxygen. Their body temperature was maintained at 37 oC throughout the scanning. 
The SPECT scans started 1 hour after the time of administration, and the acquisition lasted 45 minutes. 
To prevent movements, the animals were immobilized in a MultiCellTM Imaging Chamber (Mediso Ltd., 
Budapest, Hungary), and positioned in the center of field of view (FOV). The reconstructed voxel size was 
300 µm in 120 × 120 × 328 pixel matrix both in SPECT and CT modalities. The image acquisitions were 
started with CT imaging after intravenous injection of 99mTc-labeled EVs. The CT and subsequent SPECT 
imaging lasted 10.5 and 30 min, respectively. Reconstructed, reoriented and co-registered images were 
further analyzed with Fusion (Mediso Ltd., Budapest, Hungary) and VivoQuant (inviCRO LLC, US) 
dedicated image analysis software by placing appropriate Volume of Interests (VOI) on the organs. The 
VOI were delineated manually on each CT scans. Radioactivity concentrations in MBq/cm3 were 
determined for each volume of interest and corrected for scattering and isotopic decay in the 
reconstruction algorithm. The uptake values were measured in the following organs: heart, lungs, kidneys, 
liver, spleen, and bladder. 
Results and Discussion 
 
Fig. 1A shows the TEM images of the platinum-carbon replicas of the freeze-fractured EV sample. 
Spherical vesicles within the size range of 80 nm to 300 nm can be observed on these pictures, clearly 
demonstrating the applicability of the used isolation protocol. SEC-DLS analysis was used to characterize 
the purity of the EV sample as well as to determine the mean hydrodynamic diameter of the vesicles 
(Fig.1B). During the SEC analysis, the EVs were excluded from the pores of the used gel (Sepharose CL-
2B), and consequently they are eluted at shorter elution times (at 4.6 min in our case). The on-line DLS 
detector enabled the characterization of the mean size of the vesicle fraction, which was found to be 188 ± 
11 nm (standard deviation). Smaller objects such as lipoproteins and soluble plasma proteins enter the 
pores of the gel, which results in longer elution times (at 14.3 min in our case). Due to the smaller size of 
the plasma proteins, their contribution cannot be detected based on the light scattering signal, but the UV 
absorption clearly indicates their presence in the studied sample. 
Contamination by plasma proteins in EV samples is common when using isolation by differential 
centrifugation only. Therefore our sample was further purified prior to the radioisotope labeling. The 
purification was performed using the same Sepharose CL-2B gel that was used for the SEC-DLS analysis, 
but in a preparative manner using a 10 mL plastic tube and a gravity separation protocol. It was recently 
shown by Böing et al. that the contamination from high density lipoprotein is less than 5% and from 
plasma proteins is less than 1% in the purified EV-fraction by using this protocol.21 The latter also agrees 
with our previous experience using the Sepharose CL-2B gel.   
To the best of our knowledge no literature data is available for the radioisotope labeling of EVs. On the 
other hand, several approaches exist for the labelling of liposomes, which can be treated as model systems 
of the EVs due to the fact that the phospholipid bilayer represents the basic structural building block for 
both. The most commonly used radionuclide for liposomes labeling is 99mTc. There are several 
(afterloading and surface) radiolabeling techniques of liposomes in the literature22. The afterloading 
labeling technique based on the application of lipid soluble chelating agents23. One of the most frequently 
applied lipophilic chelator molecules is HMPAO (hexamethylpropyleneamineoxime). It is able to carry 
99mTc inside the preformed vesicle, where the lipophilic HMPAO is transformed into its hydrophilic form 
in the presence of glutathione and HMPAO is trapped22,24–32. Another afterloading method for labeling 
liposomes uses 99mTc-BMEDA. This lipophilic radionuclide complex has very good in vitro and in vivo 
stability22. The direct surface labeling with 99mTc-pertechnetate is an easy manner of liposome labeling but 
the radiochemical yield, the specific activity and the stability of the forming complex seems to be very 
low33. 
Radiolabeling of artificial exosome-mimetic nanovesicles (ENVs) prepared by extrusion of macrophage 
cells was recently reported using the 99mTc-HMPAO method which is an established technique in 
liposome research.34 The in vivo biodistribution of ENVs used as model system for real EVs was 
investigated using SPECT/CT. Although this method can be used in principle to label real EVs, the low 
labeling efficiency of the HMPAO method at low concentrations in the case of liposomes might hinder the 
successful labeling of EVs.  
In our experiment the novel organometallic aquaion, 99mTc-tricarbonyl was used for the radioisotope 
labeling of the purified EVs. This technique combines the advantages of high specific activity and small 
size of the labeling compound.35 Hence it retains the biological activity of the labeled object. The 99mTc-
tricarbonyl has been used for the labeling of a wide range of biomolecules from small tracer molecules, 
peptides, and antibodies to liposomes containing a DTPA chelater.33,36 The 99mTc-tricarbonyl binds to 
several amino acids such as histidine, methionine, and cysteine,37 consequently it was assumed that this 
aquaion will inherently bind to the surface of EVs due to the presence of membrane proteins of the 
vesicles.  After the labeling procedure, the unbound 99mTc-tricarbonyl was removed by using desalting 
columns. The used desalting column removes more than 98% of the free 99mTc-tricarbonyl according to 
our previous experience, which also agrees with the specification from the manufacturer. By measuring 
the activities of the elutes and the columns, a labeling efficiency of 38.8 ± 6.2% was obtained for the 
erythrocyte derived EVs, which is reasonable, especially if the generally low concentration of EVs is 
considered. 
Fig 2. shows a typical SPECT/CT image with the biodistribution of the labeled erythrocyte-derived EVs. 
High accumulation of the injected EVs can be observed in the liver and the spleen in accordance with 
previous fluorescent imaging studies. The activity appearing in the bladder can be attributed to the free 
99mTc-tricarbonyl as demonstrated by a control measurement with the labeling compound. The real 
advantage of modern nuclear imaging methods is that the distribution of the labeled objects can be 
quantified without the need for removing the specific organs. In order to determine the percentage of the 
radioactivity in the different organs, appropriate VOIs were used. Fig. 3 shows the distribution of the 
labeled EVs within the different organs as a percentage of the total injected radioactivity (Fig. 3A) and 
also as standardized uptake value, known as SUV (Fig. 3B). SUV is defined as the ratio of the tissue 
radioactivity concentration and the injected activity divided by the body weight (as often used in PET). A 
major advantage of preclinical SPECT imaging is its ability to produce quantitative results for 
biodistribution,38 just like PET imaging. SUV takes into account the volume of the segmented organ and 
so highlights organs with higher tissue uptake values. 
The distribution values for the labeling compound alone are also presented in Fig. 3. The distributions of 
the free 99mTc-tricarbonyl and that of the labeled EVs differ significantly, which is an evidence of the 
successful labeling. The radioactivity detected in the bladder (3% of the injected radioactivity), originates 
from the free 99mTc-tricarbonyl that corresponds to the radiochemical purity of the labeled EV sample 
(taking into account the approx. 40% labeling efficiency and the 98% efficiency of the desalting columns 
used to remove the remaining free 99mTc-tricarbonyl after labeling), which also indicates a good in vivo 
stability of the labeling. 
The main aim of the SPECT/CT investigation of the 99mTc labeled erythrocyte-derived EVs was to 
demonstrate the applicability of the developed labeling procedure for in vivo experiments and to assess the 
in vivo stability of the labeling. The deep analysis of the biodistribution of erythrocyte-derived EVs is out 
of the scope of this paper, however, it can be compared to recent studies using fluorescently labeled EVs13 
and using 99mTc-labeled exosome-mimetic nanovesicles (ENVs)34. Wiklander et al. used a lipophilic near-
infrared fluorescent dye (DiR: 1,1-dioctadecyl-3,3,3,3-tetramethy-lindotricarbocyanine iodide) that only 
fluoresces intensely when inserted into a lipid-membrane, to assess the biodistribution of EVs isolated 
from different cell lines. The obtained distribution of HEK293T cell derived EVs agrees well with our 
observation, namely high uptake of the EVs in the liver (60-80% of the total fluorescence, depending on 
the dose and way of administration), and in the spleen (10-20% of the total fluorescence). Wiklander et al. 
also investigated EVs from different sources, such as C2C12 mouse muscle cell line, B16F10 melanoma 
cells and primary immature bone marrow-derived DCs. The liver uptake was the highest among the 
organs in all cases, but interestingly, they have found differences for the extent of liver accumulation 
being the highest for the C2C12 cell-derived EVs (71 ± 1.5%) and the lowest for DC-derived EVs (46 ± 
0.9%). Confirmation of these observations using radiolabeled EVs and using SPECT/CT (which is 
superior to fluorescent imaging regarding quantitative analysis), would be an interesting application of the 
99mTc-tricarbonyl EV labelling procedure presented in this study. 
The biodistribution obtained by Hwang et al. for 99mTc-HMPAO labeled ENVs from murine macrophage 
Raw 264.7 cell line shows also great similarity with the results presented in this paper34. Hwang et al. 
prepared ENVs by extrusion of whole cells and subsequent purification by gradient ultracentrifugation. 
High concentration of ENVs can be achieved by this method compared to natural EVs, which enabled the 
99mTc-HMPAO labelling. On the other hand, the authors also mention in their manuscript that labeling of 
natural EVs with the 99mTc-HMPAO method is challenging due to the low radiochemical yield of the 
method at low EV concentrations34.  
In summary, a novel method for the radioisotope labeling of erythrocyte-derived EVs using 99mTc-
tricarbonyl complex is presented. Special attention was paid to the purity of the EV sample that was 
achieved by SEC purification. This procedure assured that only EVs were labeled, since the used 
radiolabel could have also bound to free serum proteins. Acceptable radiochemical yield was achieved by 
the use of the novel 99mTc-tricarbonyl complex, which has high affinity to biomolecules. The applicability 
of the presented radiochemical labeling procedure was demonstrated by in vivo SPECT/CT imaging 
experiments using a mouse model which also confirmed the in vivo stability of the labeling. The presented 
method might pave the way for further studies addressing the in vivo fate of EVs using nuclear imaging 
methods.  
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 Figures 
 
Fig. 1 (A) FF-TEM images of the erythrocyte-derived EVs. (B) SEC-DLS analysis of the erythrocyte-
derived EVs using Sepharose CL-2B stationary phase. Black solid line represents the UV absorption 
signal while the red solid line corresponds to the static light scattering intensity at 90˚. Both signals 
indicate the EV fraction at 4.6 min elution time. The average size of the EVs was determined by the on-
line DLS data denoted by the symbols. The peak at 14.3 min corresponds to the protein contamination 
present in the sample, which is detectable only by the UV absorption signal.  
 
Fig. 2 In vivo SPECT-CT images of the 99mTc-labelled erythrocyte-derived EVs. The 3D reconstructed 
and co-registered SPECT and CT image is shown together with sagittal, coronal, and axial images (from 
left to right). Uptake of the EVs by the liver and spleen is clearly visible on the images, while the activity 
detected in the bladder corresponds to the 99mTc-tricarbonyl complex detached from the vesicles. (For 
color coded version of this figure, the reader is referred to the web version of the article.) 
 Fig. 3 Quantitative distribution of 99mTc-labelled erythrocyte-derived EVs together with the results of the 
control measurement performed by using the 99mTc-tricarbonyl complex alone. The activities measured in 
the specified organs in the percentage of the whole-body radioactivity are shown in A, and the 
standardized uptake values for the different organs are shown in B. 
 
